Immunitybio, Inc. (IBRX) Stock Price & Analysis
Immunitybio, Inc. (IBRX) fell 4.05% to USD 7.1 as of July 25, 2026 at 04:39 UTC, according to Nexqual real-time market data.
IBRX last closed at USD 7.4; the session ranged USD 7.06–7.45 on volume of 8,495,538 shares. Market capitalization is $7.44B, with a 52-week range of USD 1.95–12.43 (NMS). Source: Nexqual, July 25, 2026 at 04:39 UTC.
Key Statistics (as of July 25, 2026 at 04:39 UTC)
| Price | USD 7.1 |
|---|---|
| Change | ▼ 4.05% (down) |
| Previous Close | USD 7.4 |
| Open | USD 7.4 |
| Day Range | USD 7.06 – 7.45 |
| 52-Week Range | USD 1.95 – 12.43 |
| Volume | 8,495,538 shares |
| Market Cap | $7.44B |
| Exchange | NMS |
Technical Analysis (IBRX)
Nexqual's technical model rates IBRX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.23 (neutral) |
| vs SMA50 | Below (USD 7.77) |
| MACD | -0.13 (negative) |
Analyst Ratings (IBRX)
Wall Street analysts rate IBRX "None" based on 3 analysts, with a mean price target of USD 13 (range USD 12–15), per Nexqual as of July 25, 2026 at 04:39 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 13 |
| High Target | USD 15 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (IBRX)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.08 |
| Revenue Estimate | $49.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.07 ▼ miss |
| 2025-12-31 | USD -0.06 vs est -0.1 ▲ beat |
| 2025-09-30 | USD -0.07 vs est -0.1 ▲ beat |
| 2025-06-30 | USD -0.1 vs est -0.1 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:39 UTC.
Financials & Fundamentals (IBRX)
| Total Revenue | $140.98M |
|---|---|
| Revenue Growth (YoY) | +167.60% |
| Gross Margin | +99.34% |
| Operating Margin | -157.88% |
| Profit Margin | +0.00% |
| Current Ratio | 6.67 |
| Total Cash | $380.88M |
| Total Debt | $1.12B |
| Free Cash Flow | $-193.70M |
Source: Nexqual, July 25, 2026 at 04:39 UTC.
Financial Health Score (IBRX)
Nexqual rates Immunitybio, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:39 UTC.
| Growth | Strong — Revenue +668% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $381M cash vs $1.12B debt |
| Cash Flow | Weak — FCF negative: -$194M, burning cash |
| Efficiency | Mixed — No data |
Ownership (IBRX)
| Insider Ownership | +62.47% |
|---|---|
| Institutional Ownership | +17.70% |
| Shares Outstanding | 1.05B |
| Float | 394.16M |
| Short % of Float | +33.94% |
Source: Nexqual, July 25, 2026 at 04:39 UTC.
Leadership (IBRX)
Immunitybio, Inc. is led by Richard Gerald Adcock (age 56), President, CEO & Director, per Nexqual as of July 25, 2026 at 04:39 UTC.
| President, CEO & Director | Richard Gerald Adcock (age 56) |
|---|---|
| Founder, Executive Chairman and Global Chief Scientific & Medical Officer | Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc. (age 72) |
| Chief Financial Officer | David C. Sachs (age 47) |
| Chief Corporate Affairs Officer & Director | Barry J. Simon (age 60) |
| Chief Technology Officer | Enrique Diloné Ph.D., RAC (age 58) |
Major Backers & Investors (IBRX)
Notable institutional backers of Immunitybio, Inc. include Shaw D.E. & Co., Inc., Fidelity, Two Sigma Investments, LP, according to Nexqual as of July 25, 2026 at 04:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Shaw D.E. & Co., Inc. | 1.2% |
| Fidelity | 0.43% |
| Two Sigma Investments, LP | 0.42% |
| Morgan Stanley | 0.38% |
| HRT Financial LP | 0.37% |
| Woodline Partners LP | 0.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.64% |
| BlackRock | 3.62% |
| State Street | 2.88% |
| Geode Capital | 0.77% |
Source: Nexqual, July 25, 2026 at 04:39 UTC.
From Immunitybio, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
- Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
- The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
- Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IOVA | Iovance Biotherapeutics, Inc. | USD 4.99 | ▼ 3.48% |
| SMMT | Summit Therapeutics Inc. | USD 13.66 | ▼ 7.33% |
| RXRX | Recursion Pharmaceuticals, Inc. | USD 2.96 | ▼ 0.67% |
| BBIO | BridgeBio Pharma, Inc. | USD 84.02 | ▲ 1.65% |
| SLS | SELLAS Life Sciences Group, Inc | USD 11.32 | ▼ 6.29% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:39 UTC. This page is informational and not investment advice.